Exact Sciences Corp (EXAS)
46.36
+0.36 (+0.78%)
USD |
NASDAQ |
Dec 02, 16:00
46.36
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 8.237B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -42.46% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.048 |
| Price to Book Value | 2.650 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.7188 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 80.42% |
News
Headline
Wire
Time (ET)
Yahoo
11/24 09:55
SA Breaking News
11/22 13:11
Yahoo
11/18 14:43
MT Newswires
11/14 07:37
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/22/2023* | 17:00 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/22/2023* | -- | Results | Q4 2022 | -- | -0.83 | -- | |
| 11/03/2022 | 17:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/03/2022 | -- | Results | Q3 2022 | -0.74 | -1.05 | 29.23% | |
| 08/02/2022 | 17:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/02/2022 | -- | Results | Q2 2022 | -0.94 | -1.04 | 10.50% | |
| 04/26/2022 | 17:00 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 04/26/2022 | -- | Results | Q1 2022 | -1.18 | -1.04 | -13.90% |
*Estimated Date/Time
Earnings
Profile
Edit
| Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of the earliest entrants in multi-cancer liquid biopsy cancer screening. |
| URL | https://www.exactsciences.com |
| Investor Relations URL | https://investor.exactsciences.com/investor-relations/default.aspx |
| HQ State/Province | Wisconsin |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Feb. 22, 2023 (est.) |
| Last Earnings Release | Nov. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of December 02, 2022.
Fundamentals
| Revenue (TTM) | 2.005B |
| Total Expenses (TTM) | 2.689B |
| Net Income (TTM) | -716.37M |
| Total Assets (Quarterly) | 6.307B |
| Total Liabilities (Quarterly) | 3.198B |
| Shareholders Equity (Quarterly) | 3.109B |
| Cash from Operations (TTM) | -300.17M |
| Cash from Investing (TTM) | 210.66M |
| Cash from Financing (TTM) | 54.19M |
Ratings
Profile
Edit
| Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of the earliest entrants in multi-cancer liquid biopsy cancer screening. |
| URL | https://www.exactsciences.com |
| Investor Relations URL | https://investor.exactsciences.com/investor-relations/default.aspx |
| HQ State/Province | Wisconsin |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Feb. 22, 2023 (est.) |
| Last Earnings Release | Nov. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| ARKG | 198.81M USD | 9.09% |
| ARKK | 484.83M USD | 6.76% |
| SPYGX | 31.81M USD | 4.30% |
| FBT | 55.44M USD | 3.88% |
| DYN1628 | 64.10M USD | 2.31% |
| DYN1798 | 21.66M USD | 2.30% |
| JACLX | 23.62M USD | 1.82% |
| ETCHX | 22.79M USD | 1.73% |
| GOFFX | 58.48M USD | 1.41% |
| XBI | 89.48M USD | 1.16% |
| BBH | 5.515M USD | 1.09% |
| LABU | 8.372M USD | 0.87% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| EXAS Tweets |